Pharmacodynamics As an AAS,<unk>  is an agonist of the androgen receptor (AR), similarly to androgens like testosterone and DHT. Its affinity for the androgen receptor is about 22% of that of dihydrotestosterone.<unk>  is not a substrate for 5α-reductase as it is already 5α-reduced, and so is not potentiated in so-called "androgenic" tissues like the skin, hair follicles, and prostate gland. This results in a greater ratio of anabolic to androgenic activity compared to testosterone. In addition, due to its 5α-reduced nature,<unk>  is non-aromatizable, and hence has no propensity for producing estrogenic effects such as gynecomastia or fluid retention.<unk>  also does not possess any progestogenic activity of significance. Because of the presence of its 17α-methyl group, the metabolism of<unk>  is<unk> erically hindered, resulting in it being orally active, although also hepatotoxic. Pharmacokinetics<unk>  has high oral bioavailability, due to the presence of its C17α alkyl group and the resistance to gastrointestinal and liver metabolism that it results in. The medication has very low affinity for human serum sex hormone-binding globulin (SHBG), about 5% of that of testosterone and 1% of that of DHT.<unk>  is metabolized in the liver, ultimately becoming glucuronide and sulfate conjugates. Its biological half-life is reported to be 9 hours when taken by mouth and 24 hours when given by intramuscular injection in the form of an aqueous suspension. It is said to have a duration of action of one week or more via intramuscular injection.
Stanozolol
Nadolol
Betaxolol
Atenolol
Oxprenolol
Acebutolol
Pindolol
Carteolol